Thyroid Inflammatory Myofibroblastic Tumor: A Rare Case, Literature Review ()
ABSTRACT
Inflammatory myofibroblastic tumor has been referred to by many different names in the past, such as plasma cell granuloma, inflammatory pseudotumor, fibrous histiocytoma, fibroxanthoma, xanthogranuloma. It was first described in the 1930s. It originates from soft tissue. It has low malignancy potential. It is rarely seen. While it is often localized in the lungs, it can rarely be localized in the thyroid gland. Its etiology and pathogenesis are unknown. Diagnosis is based on postoperative immunohistochemical evaluation. Although surgical resection is the main treatment method, there is no standard approach. Recurrence is not expected in general. However, cases of recurrence after a long period of time have also been reported. In this study, a 46-year-old female patient was presented with thyroid inflammatory myofibroblastic tumor that developed after COVID-19. Another notable point in the case is that her mother had myeloma with mutations (changes in chromosomes 11 and 14).
Share and Cite:
Sümter, H. (2024) Thyroid Inflammatory Myofibroblastic Tumor: A Rare Case, Literature Review.
Open Journal of Internal Medicine,
14, 337-342. doi:
10.4236/ojim.2024.144030.
Cited by
No relevant information.